Evidence mapPaperPMID 30355033Full record

ArticleCirculation research2018

Effect of Intracoronary Metformin on Myocardial Infarct Size in Swine.

George Techiryan, Brian R Weil, Beth A Palka, John M Canty

Open access · bronzeAbstract read
In one paragraph

Article in Circulation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Pharmaceutical Therapies for Necroptosis in Myocardial Ischemia-Reperfusion Injury.Journal of cardiovascular development and disease · 2023
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Effect of Metformin on Cardiac Metabolism and Longevity in Aged Female Mice.Frontiers in cell and developmental biology · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

George TechiryanFrom the VA WNY Health Care System and the Departments of Medicine, Pharmacology and Toxicology, Physiology and Biophysics, and Biomedical Engineering, and the Clinical and Translational Research Center of the University at Buffalo, NY.
Brian R WeilFrom the VA WNY Health Care System and the Departments of Medicine, Pharmacology and Toxicology, Physiology and Biophysics, and Biomedical Engineering, and the Clinical and Translational Research Center of the University at Buffalo, NY.
Beth A PalkaFrom the VA WNY Health Care System and the Departments of Medicine, Pharmacology and Toxicology, Physiology and Biophysics, and Biomedical Engineering, and the Clinical and Translational Research Center of the University at Buffalo, NY.
John M CantyFrom the VA WNY Health Care System and the Departments of Medicine, Pharmacology and Toxicology, Physiology and Biophysics, and Biomedical Engineering, and the Clinical and Translational Research Center of the University at Buffalo, NY.
VA Western New York Healthcare System · US

Funding

University of Buffalo Clinical and Translational Science InstituteUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Timothy F Murphy · 2022 to 2024
$11.9M
CHRONIC ADAPTATIONS TO MYOCARDIAL ISCHEMIAR01HL055324 · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 1996 to 2005
$1.7M
APOPTOSIS AND CONTRACTILITY IN ISCHEMIC CARDIOMYOPATHYR01HL061610 · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2000 to 2003
$1.6M
Preventing and Reversing Interstitial Fibrosis in HFpEFI01BX002659 · VA WESTERN NEW YORK HEALTHCARE SYSTEM · 2025 to 2025
BLRD VA I01 BX002659NCATS NIH HHS UL1 TR001412NHLBI NIH HHS R01 HL055324NHLBI NIH HHS R01 HL061610
6 · The paper itself

Abstract

rationaleMetformin has been demonstrated to decrease infarct size (IS) and prevent postinfarction left ventricular (LV) remodeling in rodents when given intravenously at the time of reperfusion. It remains unclear whether similar cardioprotection can be achieved in a large animal model.

objectiveThe objective of this study was to determine whether intravascular infusion of metformin at the time of reperfusion reduces myocardial IS in a porcine model of acute myocardial infarction. METHODS AND

resultsIn a blinded and randomized preclinical study, closed-chest swine (n=20) were subjected to a 60-minute left anterior descending coronary artery occlusion to produce myocardial infarction. Contrast-enhanced computed tomography was performed during left anterior descending coronary artery occlusion to assess the ischemic area-at-risk. Animals were randomized to receive either metformin or vehicle as an initial intravenous bolus (5 mg/kg) 8 minutes before reperfusion, followed by a 15-minute left coronary artery infusion (1 mg/kg per minute) commencing with the onset of reperfusion. Echocardiography and computed tomographic imaging of LV function were performed 1 week later, at which time the heart was removed for postmortem pathological analysis of area-at-risk and IS (triphenyltetrazolium chloride). Baseline variables including hemodynamics and LV function were similar between groups. Peak circulating metformin concentrations of 374±35 µmol/L were achieved 15 minutes after reperfusion. There was no difference between the area-at-risk as a percent of LV mass by computed tomography (vehicle: 20.7%±1.1% versus metformin: 19.7%±1.3%; P=0.59) or postmortem pathology (22.4%±1.2% versus 20.2%±1.2%; P=0.21). IS relative to area-at-risk averaged 44.5%±5.0% in vehicle-treated versus 38.2%±6.8% in metformin-treated animals ( P=0.46). There was no difference in global function 7 days after myocardial infarction as assessed by echocardiography or computed tomographic ejection fraction (56.2%±2.6% versus 56.3%±2.4%; P=0.98).

conclusionsIn contrast to rodent hearts, postconditioning with high-dose metformin administered immediately before reperfusion does not reduce IS or improve LV function 7 days after myocardial infarction in swine. These results reinforce the importance of rigorously testing therapies in large animal models to facilitate clinical translation of novel cardioprotective therapies.

Indexed as

AnimalsCardiovascular AgentsDisease Models, AnimalDrug Administration ScheduleEchocardiographyInfusions, Intra-ArterialInjections, IntravenousMetforminMultidetector Computed TomographyMyocardial InfarctionMyocardiumSpecies SpecificityStroke VolumeSus scrofaTime FactorsVentricular Function, LeftCardiovascular AgentsMetformininfarctionmetforminmodels, animalmyocardial infarctionventricular remodeling

Identifiers

PMID30355033
PMCPMC6207210
OpenAlexW2888378829

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.